CRISPR Therapeutics (NASDAQ:CRSP) Stock: Insider Samarth Kulkarni Sells 47,837 Shares

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 47,837 shares of the firm’s stock in a transaction dated Monday, October 19th. The stock was sold at an average price of $49.78, for a total transaction of $2,381,325.86. Following the sale, the chief executive officer owned 311,899 shares of the company’s stock, valued at $15,526,332.22. This trade represents a 13.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Samarth Kulkarni also recently made the following trade(s):

• On Wednesday, October 14th, Samarth Kulkarni sold 4,098 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $49.26, for a total transaction of $201,867.48.

CRISPR Therapeutics Price Performance

CRSP opened at $50.50 on Thursday. The company has a current ratio of 17.85, a quick ratio of 17.85 and a debt-to-equity ratio of 0.34. CRISPR Therapeutics AG has a twelve month low of $44.12 and a twelve month high of $70.74. The company’s 50-day moving average price is $54.77 and its two-hundred day moving average price is $53.31.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share for the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. The company had revenue of $10.18 million for the quarter. As a group, equities analysts predict that CRISPR Therapeutics AG will post -4.48 EPS for the current year.

Analyst Ratings Changes

CRSP has been the subject of several research reports. UBS Group began coverage on CRISPR Therapeutics in a report on Thursday, October 15th. They set a “neutral” rating and a $52.00 price objective for the company. The Goldman Sachs Group restated a “neutral” rating and issued a $55.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, August 6th. Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Thursday, October 15th. HC Wainwright reaffirmed a “buy” rating on shares of CRISPR Therapeutics in a research report on Friday, October 9th. Finally, Wall Street Zen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, CRISPR Therapeutics has an average rating of “Moderate Buy” and an average target price of $65.75.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Affinity Asset Advisors LLC purchased a new stake in shares of CRISPR Therapeutics during the first quarter worth $7,136,000. KBC Group NV boosted its holdings in shares of CRISPR Therapeutics by 3,999.9% in the first quarter. KBC Group NV now owns 116,847 shares of the company’s stock worth $5,558,000 after acquiring an additional 113,997 shares during the period. Shah Wealth Advisors LLC bought a new position in shares of CRISPR Therapeutics in the second quarter worth $3,767,000. Monashee Investment Management LLC purchased a new position in shares of CRISPR Therapeutics in the first quarter valued at $2,378,000. Finally, Quantinno Capital Management LP grew its position in shares of CRISPR Therapeutics by 613.5% in the first quarter. Quantinno Capital Management LP now owns 47,989 shares of the company’s stock valued at $2,283,000 after purchasing an additional 41,263 shares in the last quarter. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.